{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017657","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.820867+00:00","generated_at":"2026-06-08T18:49:42.286652+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protalix Q3 revenues from goods up 16% to $10.2M; net loss narrows to $1.9M","bullets":["Revenues from selling goods $10.2M (+16% YoY), driven by Elfabrio sales to Chiesi after FDA/EMA approvals.","License and R&D service revenues fell 96% to $0.2M as extension studies transferred to Chiesi.","Net loss improved to $1.9M ($0.03 basic EPS) vs $3.6M loss ($0.07 EPS) in Q3 2022.","Cash and equivalents $41.0M; PRX-115 Phase I for gout enrolled 32 patients, results expected mid-2024.","Regulatory: UK MHRA and Swissmedic approved Elfabrio; Dr. Eliot Forster appointed Board Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017657","json":"https://secwatch.observer/filing/0001558370-23-017657.json","markdown":"https://secwatch.observer/filing/0001558370-23-017657.md","text":"https://secwatch.observer/filing/0001558370-23-017657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/0001558370-23-017657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/plx-20231106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:49:42.286652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"881a17a2a60724d5690bdce6186693f3cb0c890e","claim":"Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 6, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/0001558370-23-017657-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}